AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Embla Medical hf

Transaction in Own Shares Sep 2, 2019

8210_rns_2019-09-02_285bcadf-50e4-430d-9182-b22597691d74.html

Transaction in Own Shares

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

Announcement no. 50/2019

2 September 2019 

Transactions in relation to share buyback program

On 14 May 2019, Össur hf. initiated a share buy-back program, see Company announcement no. 31/2019.

The purpose of the share buyback program is to reduce the Company's share capital and adjust the capital structure by distributing capital to shareholders in line with the Company's Capital Structure and Dividend Policy. The program will end no later than 31 December 2019. The Company may purchase up to 5,000,000 shares under the program, corresponding to 1.2% of the current share capital. The total consideration for shares purchased under the program shall not exceed USD 10 million.

The following transactions have been made under the program in week 16, the period 26 August 2019 – 30 August 2019:

Transactions
Date No. of shares Avg. purchase

price in DKK
Transaction

value in DKK
26 August 2019 12,291 44.75 550,063
27 August 2019 11,554 46.13 532,946
28 August 2019 10,000 47.84 478,386
29 August 2019 9,999 47.95 479,409
30 August 2019 10,000 47.91 479,058
Total 53,844 46.79 2,519,862

Össur has acquired 1,586,565 shares under the program at the average price of DKK 41.59. Following the above transactions Össur’s holding of own shares is 2,453,883 corresponding to 0.58% of the Company’s total share capital.

The share buyback program on Nasdaq Copenhagen is carried out in accordance with Regulation No. 596/2014 of the European Parliament and of the Council on market abuse ("MAR"), and the Commission delegated regulation No. 2016/1052.

Further information

David Hreidarsson, Investor Relations, [email protected], +354 515 1380

Össur press releases by e-mail

If you wish to receive Össur press releases by e-mail please register at http://www.ossur.com/investors

About Össur

Össur (NASDAQ OMX: OSSR) is a global leader in non-invasive orthopaedics that help people live a life without limitations.  Its business is focused on improving people’s mobility through the delivery of innovative technologies within the fields of Prosthetics and Bracing & Supports.  A recognized “Technology Pioneer,” Össur invests significantly in research and product development—its award-winning designs ensuring a consistently strong position in the market. Successful patient and clinical outcomes are further empowered via Össur’s educational programs and business solutions.  Headquartered in Iceland, Össur has major operations in the Americas, Europe and Asia, with additional distributors worldwide. www.ossur.com

Attachment

Talk to a Data Expert

Have a question? We'll get back to you promptly.